|
Status
|
In progress
|
| Process |
STA pre-2018
|
| ID number |
974
|
Provisional Schedule
| Expected publication |
24 October 2018 |
Project Team
| Project lead |
Jeremy Powell |
Email enquiries
Consultees
| Companies sponsors |
Janssen |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
NHS Bradford Districts CCG |
| |
NHS Heywood, Middleton and Rochdale CCG |
| |
Welsh Government |
| Patient carer groups |
African Caribbean Leukaemia Trust |
| |
Anthony Nolan |
| |
Black Health Agency |
| |
Bloodwise |
| |
Cancer Black Care |
| |
Cancer Equality |
| |
Cancer52 |
| |
DKMS |
| |
HAWC |
| |
Helen Rollason Cancer Charity |
| |
Independent Cancer Patients Voice |
| |
Leukaemia Cancer Society |
| |
Leukaemia CARE |
| |
Lymphoma Association |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie Cancer Care |
| |
Muslim Council of Britain |
| |
Myeloma UK |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Tenovus Cancer Care |
| Professional groups |
Association of Cancer Physicians |
| |
British Blood Transfusion Society |
| |
British Committee for Standards in Haematology |
| |
British Geriatrics Society |
| |
British Institute of Radiology |
| |
British Psychosocial Oncology Society |
| |
British Society for Haematology |
| |
British Transplantation Society |
| |
Cancer Research UK |
| |
NHS Blood and Transplant |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society and College of Radiographers |
| |
UK Health Forum |
| |
UK Myeloma Forum |
| |
UK Clinical Pharmacy Association |
| |
UK Oncology Nursing Society |
Commentators
| Associated public health groups |
Public Health England |
| |
Public Health Wales |
| Comparator companies |
Amgen (carfilzomib) |
| |
Celgene (lenalidomide and pomalidomide) |
| |
Concordia International (dexamethasone) |
| |
Dr Reddy’s Laboratories (bendamustine) |
| |
Janssen (bortezomib, daratumumab and doxorubicin) |
| |
Medac UK (bendamustine, doxorubicin) |
| |
Napp Pharmaceuticals (bendamustine) |
| |
Novartis (panobinostat) |
| |
Zentiva (bendamustine) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Alliance |
| |
NHS Commercial Medicines Unit |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Bloodwise |
| |
Cochrane Haematological Malignancies Group |
| |
Institute of Cancer Research |
| |
Leuka |
| |
Leukaemia Busters |
| |
MRC Clinical Trials Unit |
| |
National Cancer Research Institute |
| |
National Cancer Research Network |
| |
National Institute for Health Research |
|
Date
|
Update
|
|
03 January 2018
|
Invitation to participate |
|
02 August 2016 - 31 August 2016
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
|
08 June 2016
|
Referral |
|
08 June 2016
|
In progress, Topic referred |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance